Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 169

1.

Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver.

Barreiro P, Vispo E, Poveda E, Fernández-Montero JV, Soriano V.

Clin Infect Dis. 2013 Feb;56(4):560-6. doi: 10.1093/cid/cis915. Epub 2012 Oct 22.

PMID:
23090932
2.

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.

Bailly F, Pradat P, Virlogeux V, Zoulim F.

Dig Dis. 2015;33(4):613-23. doi: 10.1159/000375359. Epub 2015 Jul 6.

PMID:
26159282
3.

HCV direct-acting antiviral agents: the best interferon-free combinations.

Schinazi R, Halfon P, Marcellin P, Asselah T.

Liver Int. 2014 Feb;34 Suppl 1:69-78. doi: 10.1111/liv.12423. Review.

PMID:
24373081
4.

[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].

Horváth G, Halász T, Makara M, Hunyady B.

Orv Hetil. 2015 May 24;156(21):841-8. doi: 10.1556/650.2015.30177. Review. Hungarian.

PMID:
26038991
5.

Current prospects for interferon-free treatment of hepatitis C in 2012.

Stedman CA.

J Gastroenterol Hepatol. 2013 Jan;28(1):38-45. doi: 10.1111/jgh.12028. Review.

PMID:
23137126
6.

Interferon-free strategies with a nucleoside/nucleotide analogue.

Feld JJ.

Semin Liver Dis. 2014 Feb;34(1):37-46. doi: 10.1055/s-0034-1371009. Epub 2014 Apr 29. Review.

PMID:
24782257
7.

Daclatasvir plus sofosbuvir for HCV infection: an oral combination therapy with high antiviral efficacy.

Asselah T.

J Hepatol. 2014 Aug;61(2):435-8. doi: 10.1016/j.jhep.2014.04.042. Epub 2014 May 6. No abstract available.

8.

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.

Herbst DA, Reddy KR.

Expert Opin Investig Drugs. 2013 Oct;22(10):1337-46. doi: 10.1517/13543784.2013.826189. Epub 2013 Aug 9. Review.

PMID:
23931586
9.

Current race in the development of DAAs (direct-acting antivirals) against HCV.

De Clercq E.

Biochem Pharmacol. 2014 Jun 15;89(4):441-52. doi: 10.1016/j.bcp.2014.04.005. Epub 2014 Apr 13.

PMID:
24735613
10.

Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.

Asselah T, Marcellin P.

Liver Int. 2014 Feb;34 Suppl 1:60-8. doi: 10.1111/liv.12424. Review.

PMID:
24373080
11.

Recent advances in the treatment of hepatitis C.

Dhingra A, Kapoor S, Alqahtani SA.

Discov Med. 2014 Oct;18(99):203-8. Review.

12.

Sofosbuvir (Sovaldi) for the treatment of hepatitis C.

Lam B, Henry L, Younossi Z.

Expert Rev Clin Pharmacol. 2014 Sep;7(5):555-66. doi: 10.1586/17512433.2014.928196. Epub 2014 Jun 11. Review.

PMID:
24918162
13.

Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.

Yang SS, Kao JH.

Expert Rev Gastroenterol Hepatol. 2015 Jan;9(1):9-20. doi: 10.1586/17474124.2014.953930. Epub 2014 Aug 31. Review.

PMID:
25174254
14.

Sofosbuvir as backbone of interferon free treatments.

Bourlière M, Oules V, Ansaldi C, Adhoute X, Castellani P.

Dig Liver Dis. 2014 Dec 15;46 Suppl 5:S212-20. doi: 10.1016/j.dld.2014.09.024. Epub 2014 Nov 6. Review.

15.

Interferon-free, direct-acting antiviral therapy for chronic hepatitis C.

Gutierrez JA, Lawitz EJ, Poordad F.

J Viral Hepat. 2015 Nov;22(11):861-70. doi: 10.1111/jvh.12422. Epub 2015 Jun 17. Review.

PMID:
26083155
16.

Sofosbuvir for the treatment of hepatitis C virus.

Asselah T.

Expert Opin Pharmacother. 2014 Jan;15(1):121-30. doi: 10.1517/14656566.2014.857656. Epub 2013 Nov 30. Review.

PMID:
24289735
17.

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

Hill A, Khoo S, Fortunak J, Simmons B, Ford N.

Clin Infect Dis. 2014 Apr;58(7):928-36. doi: 10.1093/cid/ciu012. Epub 2014 Jan 6.

18.

Emerging therapies for hepatitis C.

Kim DY, Ahn SH, Han KH.

Gut Liver. 2014 Sep;8(5):471-9. doi: 10.5009/gnl14083. Epub 2014 Aug 18. Review.

19.

Sofosbuvir, a novel nucleotide analogue inhibitor used for the treatment of hepatitis C virus.

Summers BB, Beavers JW, Klibanov OM.

J Pharm Pharmacol. 2014 Dec;66(12):1653-66. doi: 10.1111/jphp.12294. Epub 2014 Aug 31. Review.

PMID:
25175944
20.

Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.

Kronenberger B, Zeuzem S.

Curr Gastroenterol Rep. 2009 Feb;11(1):15-21.

PMID:
19166654

Supplemental Content

Support Center